Balancing body and mind: selecting the optimal antipsychotic

View/ Open
File version
Version of Record (VoR)
Author(s)
Siskind, D
Kisely, S
Griffith University Author(s)
Year published
2019
Metadata
Show full item recordAbstract
In The Lancet, Maximilian Huhn and colleagues5 report a network meta-analysis of antipsychotic medications for the acute management of schizophrenia that includes 402 studies of 32 different antipsychotics with data for 53 463 participants (mean age 37·40 years [SD 5·96], 29 949 [56·02%] male and 23 514 [43·98%] female, mean illness duration 11·90 years [SD 5·19]). This is the largest and most comprehensive meta-analysis of antipsychotic medication for acute psychosis to date. The use of a network meta-analysis allows comparisons between agents that might not have been directly compared in clinical trials. Other strengths ...
View more >In The Lancet, Maximilian Huhn and colleagues5 report a network meta-analysis of antipsychotic medications for the acute management of schizophrenia that includes 402 studies of 32 different antipsychotics with data for 53 463 participants (mean age 37·40 years [SD 5·96], 29 949 [56·02%] male and 23 514 [43·98%] female, mean illness duration 11·90 years [SD 5·19]). This is the largest and most comprehensive meta-analysis of antipsychotic medication for acute psychosis to date. The use of a network meta-analysis allows comparisons between agents that might not have been directly compared in clinical trials. Other strengths include consideration of the placebo response rate, study sample size, publication year, baseline severity, sponsorship, comparability of doses, and patient demographics, using both meta-regression and sensitivity analyses of excluding poorer-quality studies. None of these factors greatly altered outcomes.
View less >
View more >In The Lancet, Maximilian Huhn and colleagues5 report a network meta-analysis of antipsychotic medications for the acute management of schizophrenia that includes 402 studies of 32 different antipsychotics with data for 53 463 participants (mean age 37·40 years [SD 5·96], 29 949 [56·02%] male and 23 514 [43·98%] female, mean illness duration 11·90 years [SD 5·19]). This is the largest and most comprehensive meta-analysis of antipsychotic medication for acute psychosis to date. The use of a network meta-analysis allows comparisons between agents that might not have been directly compared in clinical trials. Other strengths include consideration of the placebo response rate, study sample size, publication year, baseline severity, sponsorship, comparability of doses, and patient demographics, using both meta-regression and sensitivity analyses of excluding poorer-quality studies. None of these factors greatly altered outcomes.
View less >
Journal Title
The Lancet
Volume
394
Issue
10202
Copyright Statement
© The Author(s) 2019. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International (CC BY-NC-ND 4.0) License, which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
Subject
Biomedical and clinical sciences